Search Within

Fiyinfolu Oladele Balogun

  1. "Radiation Oncology, Department of"
Formats
  1. Journal Article (2)
  2. Meeting Abstract (2)
Groups
  1. CTCR Scholars (4)
  2. Center for Pancreatic Cancer Research (4)
  3. Department of Medicine (4)
  4. Department of Pathology and Laboratory Medicine (4)
  5. GSK Faculty (4)
  6. Gastrointestinal Oncology Service (4)

More Groups

People
  1. Anna Varghese (4)
  2. Catherine O'Connor (4)
  3. David Kelsen (4)
  4. Eileen O'Reilly (4)
  5. Joanne Chou (4)
  6. Kenneth Yu (4)

More People

Years
  1. 2025 (1)
  2. 2024 (1)
  3. 2023 (1)
  4. 2022 (1)
Publications
  1. Annals of Oncology (1)
  2. Clinical Cancer Research (1)
  3. JNCI: Journal of the National Cancer Institute (1)
  4. Journal of Clinical Oncology (1)
Publishers
  1. Oxford University Press (2)
  2. American Association for Cancer Research (1)
  3. American Society of Clinical Oncology (1)

Results (4)

Export to EndNote / Excel | PubMed

Citation style sort is year ascending, and then by author or title. Author ascending is default.
  • Adjuvant modified FOLFIRINOX for resected pancreatic adenocarcinoma: Clinical insights and genomic features from a large contemporary cohort
    Journal Article

    Keane, F.; O’Connor, C.; Moss, D.; Chou, J. F.; Perry, M. A.; Crowley, F.; Saxena, P.; Chan, A.; Schoenfeld, J. D.; Singhal, A.; more...
    JNCI: Journal of the National Cancer Institute (2025)

    Fulltext@MSK | Save
  • Phase II trial of Pembrolizumab and OLApaRib (POLAR) maintenance for select patients (pts) with metastatic pancreatic cancer (mPC) with (A) homologous recombination deficiency (HRD), (B) non-core HRD (ncHRD) and (C) exceptional response to platinum
    Meeting Abstract

    Park, W.; O'Connor, C.; Chou, J.; Schwartz, C.; Larsen, M.; Varghese, A.; Yu, K.; Balogun, F.; Yang, J.; Katz, S.; more...
    Annals of Oncology (2024)

    Fulltext@MSK | Save
  • Phase 2 trial of pembrolizumab and olaparib (POLAR) maintenance for patients (pts) with metastatic pancreatic cancer (mPDAC): Two cohorts B non-core homologous recombination deficiency (HRD) and C exceptional response to platinum-therapy
    Meeting Abstract

    Park, W.; O'Connor, C.; Chou, J. F.; Schwartz, C.; Varghese, A. M.; Larsen, M.; Balogun, F.; Brenner, R.; Yu, K. H.; Diguglielmo, E.; more...
    Journal of Clinical Oncology (2023)

    Fulltext@MSK | Save
  • Clinico-genomic characterization of ATM and HRD in pancreas cancer: Application for practice
    Journal Article

    Park, W.; O'Connor, C. A.; Bandlamudi, C.; Forman, D.; Chou, J. F.; Umeda, S.; Reyngold, M.; Varghese, A. M.; Keane, F.; Balogun, F.; more...
    Clinical Cancer Research (2022)

    Fulltext@MSK | Save